Vemurafenib and radiosensitization

JAMA Dermatology

Volumn 149, Issue 7, 2013, Pages 855-857

  Boussemart, Lise ^a   Boivin, Catherine ^b   Claveau, Joël ^b   Tao, Yun Gan ^a   Tomasic, Gorana ^a   Routier, Emilie ^a   Mateus, Christine ^a   Deutsch, Eric ^a   Robert, Caroline ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETAMETHASONE VALERATE; BROMAZEPAM; CELECOXIB; CITALOPRAM; CORTICOSTEROID; DACARBAZINE; FOTEMUSTINE; FUROSEMIDE; HYDROMORPHONE; IPILIMUMAB; IRBESARTAN; MORPHINE; NIFEDIPINE; PARACETAMOL; PREGABALIN; TEMAZEPAM; VEMURAFENIB;

ADULT; ARTICLE; BLEEDING; BONE METASTASIS; BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL FEATURE; DERMATITIS; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; ECZEMA; ERYTHEMA; FEMALE; GENE MUTATION; HUMAN; INFLAMMATORY INFILTRATE; MALE; MELANOMA; ONCOGENE; PAIN; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; RADIOSENSITIZATION; SKIN BIOPSY; SKIN METASTASIS;

ADULT; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RADIATION TOLERANCE; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84880645432     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.4200     Document Type: Article

References (13)

1. Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol. 2001;59(3):237-245.
2. Fontana JA. Radiation recall associated with VP-16-213 therapy. Cancer Treat Rep. 1979;63(2): 224-225.
3. Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol. 2006;54(1):28-46.
4. Isomura M, Oya N, Tachiiri S, et al. IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis. Clin Cancer Res. 2008;14(20): 6683-6689.
5. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
6. Haas RL, de Klerk G. An illustrated case of doxorubicin-induced radiation recall dermatitis and a review of the literature. Neth J Med. 2011;69(2): 72-75.
7. Chen SS, Strauss JB, Shah AP, Rao RD, Bernard DA, Griem KL. Radiation recall reaction with docetaxel administration after accelerated partial breast irradiation with electronic brachytherapy. Brachytherapy. 2009;8(3):331-334.
8. Squire S, Chan M, Feller E, Mega A, Gold R. An unusual case of gemcitabine-induced radiation recall. Am J Clin Oncol. 2006;29(6):636. doi:10.1097/01.coc.0000182426.43595.25.
9. Kundranda MN, Daw HA. Tamoxifen-induced radiation recall dermatitis. Am J Clin Oncol. 2006;29(6):637-638.
10. Chung C, Dawson LA, Joshua AM, Brade AM. Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anticancer Drugs. 2010;21(2): 206-209.
11. Ristić B. Radiation recall dermatitis. Int J Dermatol. 2004;43(9):627-631.
12. Camidge R, Price A. Radiation recall dermatitis may represent the Koebner phenomenon. J Clin Oncol. 2002;20(19):4130. doi:10.1200/JCO.2002.99.148.
13. Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med. 2012;366(5): 480-481.